Research Summary

I am involved with the Urologic, Thoracic, Orthopedic and Gastrointestinal Oncology programs at UCSF. I spend 4 days per week providing clinical coverage for the above programs program. On average, I see 6 new patient consultations per week and 15 patients on treatment. I am responsible for patient simulations, treatment planning, supervision of external-beam radiation therapy, on-treatment visits, and follow-up visits. In addition, I am involved in the brachytherapy, intra-operative radiation therapy and stereotactic body radiotherapy programs. I attend tumor boards for GU, Thoracic, GI, orthopedic oncology programs and at the Veterans Administration Hospital. I work very closely with radiation oncology residents and medical students in all the above activities. I am the Director of the CyberKnife Radiosurgery Program at UCSF and proctor other faculty in this area. As Vice Chair of clinical services I over see clinical operations at the Mount Zion site, and over see the site directors at both the Parnassus Mission Bay and Washington Hospital.

Education

University of Chicago, Chicago, IL, B.A., 1988, Chemistry
University of Chicago, Chicago, IL, Ph.D., 1994, Pathology
University of Chicago, Chicago, IL, M.D., 1996, Medicine
Kaiser Permanente Medical Center, 1996-1997, Internship Medicine
University of California, San Francisco, 1997-2001, Resident Radiation Oncology

Honors & Awards

  • 1988-96
    NIH Medical Scientist Training Program Fellowship, University of Chicago, Chicago, IL
  • 1998-99
    NIH National Research Service Award, Department of Radiation Oncology, University of California San Francisco
  • 2000
    RSNA Research and Education Foundation Roentgen Resident/Fellow Research Award
  • 2001-02
    Clinical Investigator Research Program Recipient, University of California San Francisco
  • 2002
    Invited speaker at the Radiation Oncology Young Investigator's Symposium, Bethesda, MD,
  • 2002-03
    UCSF Prostate Cancer SPORE Developmental Research Program Award
  • 2003-05
    RSNA Research Scholar Award
  • 2003-05
    American Society of Therapeutic Radiation and Oncology Junior Faculty Award

Selected Publications

  1. Chen WC, Li Y, Lazar A, Altan A, Descovich M, Nano T, Ziemer B, Sudhyadhom A, Cunha A, Thomas H, Gottschalk A, Hsu IC, Roach M Stereotactic body radiotherapy and high-dose rate brachytherapy boost in combination with intensity modulated radiotherapy for localized prostate cancer: a single-institution propensity score matched analysis.  View on PubMed
  2. Wu SY, Lazar AA, Gubens MA, Blakely CM, Gottschalk AR, Jablons DM, Jahan TM, Wang VEH, Dunbar TL, Wong ML, Chan JW, Guthrie W, Belkora J, Yom SS Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.  View on PubMed
  3. Chen WC, Baal JD, Baal U, Pai J, Gottschalk A, Boreta L, Braunstein SE, Raleigh DR Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients.  View on PubMed
  4. Woldemariam S, Nagpal J, Hill T, Li J, Schneider MW, Shankar R, Futey M, Varshney A, Ali N, Mitchell J, Andersen K, Barsi-Rhyne B, Tran A, Costa WS, Krzyzanowski MC, Yu YV, Brueggemann C, Hamilton OS, Ferkey DM, VanHoven M, Sengupta P, Gottschalk A, L'Etoile N Using a Robust and Sensitive GFP-Based cGMP Sensor for Real-Time Imaging in Intact Caenorhabditis elegans.  View on PubMed
  5. Kallianos KG, Muhoozi BN, Gottschalk A, Yom SS, Chan JW, Henry TS, Elicker BM, Ordovas KG, Naeger DM Dedicated Diagnostic Radiology/Radiation Oncology Rounds: Added Value Beyond Traditional Tumor Boards.  View on PubMed
  6. Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach M, Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer.  View on PubMed
  7. Chapman CH, Braunstein SE, Pouliot J, Noworolski SM, Weinberg V, Cunha A, Kurhanewicz J, Gottschalk AR, Roach MI, Hsu IC Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy.  View on PubMed
  8. Chapman CH, McGuinness C, Gottschalk AR, Yom SS, Garsa AA, Anwar M, Braunstein SE, Sudhyadhom A, Keall P, Descovich M Influence of respiratory motion management technique on radiation pneumonitis risk with robotic stereotactic body radiation therapy.  View on PubMed
  9. Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II.  View on PubMed
  10. McLaughlin PW, Liss AL, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, Movsas B, Prestidge BR, Showalter TN, Taira AV, Vapiwala N, Davis BJ, ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer.  View on PubMed
  11. Paulsson AK, Yom SS, Anwar M, Pinnaduwage D, Sudhyadhom A, Gottschalk AR, Chang AJ, Descovich M Respiration-Induced Intraorgan Deformation of the Liver: Implications for Treatment Planning in Patients Treated With Fiducial Tracking.  View on PubMed
  12. Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer.  View on PubMed
  13. , Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.  View on PubMed
  14. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes.  View on PubMed
  15. Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity.  View on PubMed
  16. Zhang L, Johnson J, Gottschalk AR, Chang AJ, Hsu IC, Roach M, Seymour ZA Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer.  View on PubMed
  17. Wahl M, Descovich M, Shugard E, Pinnaduwage D, Sudhyadhom A, Chang A, Roach M, Gottschalk A, Chen J Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.  View on PubMed
  18. Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery.  View on PubMed
  19. Pinnaduwage DS, Descovich M, Lometti MW, Varad B, Roach M, Gottschalk AR An Evaluation of Robotic and Conventional IMRT for Prostate Cancer: Potential for Dose Escalation.  View on PubMed
  20. Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M, Gottschalk AR Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.  View on PubMed

Go to UCSF Profiles, powered by CTSI